Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809). [electronic resource]
Producer: 20160620Description: 2469-74 p. digitalISSN:- 2164-554X
- Aged
- Antibodies, Neoplasm -- blood
- Antineoplastic Agents -- adverse effects
- CD4-Positive T-Lymphocytes -- immunology
- CD8-Positive T-Lymphocytes -- immunology
- Cancer Vaccines -- administration & dosage
- Docetaxel
- Humans
- Immunoglobulin G -- blood
- Male
- Middle Aged
- Neoplasm Metastasis -- drug therapy
- Prostate-Specific Antigen -- blood
- Prostatic Neoplasms, Castration-Resistant -- drug therapy
- Survival Analysis
- Taxoids -- adverse effects
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.